Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery

Type 2 Diabetes Clinical Trial

Official title:

The Safety and Efficacy of Correcting Preoperative Hyperglycemia in Ambulatory Surgical Patients With Diabetes: A Randomized Controlled Clinical Trial

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01971047
• Other study ID #: IRB00067662
• Status: Withdrawn
• Phase: Phase 4
• First received: September 26, 2013
• Last updated: March 13, 2017
• Start date: October 2013
• Est. completion date: September 2018

Study information

• Verified date: March 2017
• Source: Emory University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the safety and efficacy of intravenous (IV) administration of FDA approved regular human insulin and subcutaneous (SC) administration of humalog, a rapid-acting insulin analog (a synthetic insulin), for correction of hyperglycemia (high blood sugar) during the immediate preoperative period in patients with diabetes having outpatient surgery at the Emory Ambulatory Surgical Center (ASC).

In this randomized controlled clinical trial patients with diabetes will be administered corrective doses of IV regular insulin or SC humalog for preoperative hyperglycemia to determine whether SC humalog results in improved intra and post-operative blood sugar control.The most common current practice at Emory University in the ambulatory surgical setting is IV administration of regular insulin for treatment of pre-operative hyperglycemia. Subjects will not be paid for their participation and will be assured of treatment for their hyperglycemia regardless of study participation.

Description:

Investigators plan to randomize a total of 200 male and female subjects with type 1 and type 2 diabetes,having an out patient surgical procedure, meeting inclusion criteria to receive corrective doses of IV regular insulin (Group I) or SC humalog insulin (Group II). The dosing formula is per Emory University Outpatient Surgical Center protocol for treating hyperglycemia and is the same for both groups. All patients with diabetes will undergo a blood sugar measurement upon arrival to the ASC using the Accuchek blood glucose meter. An admission blood sugar of >180 in a patient with diabetes qualifies the patient for study screening. Subjects will be approached after confirmation of eligibility for the study. Randomization, then treatment, will occur immediately following written informed consent. Demographic data will be recorded.A medical history with detailed history of diabetes will be obtained and surgical and anesthesia details and length of stay recorded. Blood sugar levels will be checked hourly until the patient is ready for discharge. Subsequent treatment will follow the hyperglycemia protocol. All blood sugar results and doses of insulin will be recorded. The subject's participation will end at the time of discharge from the Ambulatory Surgical Center.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 2018
• Est. primary completion date: September 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Male or female patients between the ages of 18 and 80 years with type 1 and type 2 diabetes

• patients undergoing ambulatory surgery

• a known history of diabetes for > 3 months treated with diet, oral antidiabetic agents and/or insulin therapy

• subjects with an admission/randomization Blood glucose> 180 and < 400 mg/dl

• Patients willing and able to provide informed consent

Exclusion Criteria:

• Age < 18 or > 80

• Subjects with increased blood glucose concentration, but without a history of diabetes (stress hyperglycemia)

• Patients on an insulin pump

• Patients with a history of clinically significant hepatic disease (cirrhosis, jaundice, end-stage liver disease, portal hypertension) and end- stage renal disease

• Current or recent (within 3 months) treatment with oral or injectable corticosteroid, parenteral nutrition and immunosuppressive treatment

• Mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study

• Female subjects whom are pregnant or breast-feeding at time of qualifying outpatient procedure

Related Conditions & MeSH terms

• Diabetes Mellitus
• Hyperglycemia
• Type 1 Diabetes
• Type 2 Diabetes

Intervention

Drug:
• Regular Insulin
Group 1 Treatment Arm,Follow dosing for BG >180 per the following formula: Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin Consider repeating dose if BG>240 mg/dl after 2 hours of initial dose
• Humalog
Group 2 treatment arm. Follow dosing for Blood glucose > 180, per the following formula: Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin Consider repeating dose if BG>240 mg/dl after 2 hours of initial dose

Locations

Country	Name	City	State
United States	Emory Healthcare Ambulatory Surgical Center	Atlanta	Georgia

Sponsors (1)

Lead Sponsor	Collaborator
Emory University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	BG concentration differences at 1 and 2 hours post intervention and post operatively	Compare the difference in Blood glucose concentration at one and two hours after the administration of corrective doses of regular and humalog insulin and immediately following ambulatory surgery.	one and two hours post intervention, post operative period
Secondary	Number and percentage of target BG readings	Investigators will determine the number and percentage of patients in each group with BG readings within the target range ( 80-180 mg/dl)	From time of treatment until patient discharge (an average of three hours, less than one day)
Secondary	Episodes of hypoglycemia	Investigators will assess if there is any difference in the number of hypoglycemic events between the two treatment groups and further assess the rate and frequency of hypoglycemia (<70 mg/dl) and severe hypoglycemia (<40 mg/dl).	time of intervention to time of patient discharge (an average of three hours, less than one day)
Secondary	Episodes of hyperglycemia	Investigators will calculate the number of patients and percent of BG readings with hyperglycemia (>180 mg/dl) and severe hyperglycemia (>300 mg/dl)in each group.	time of treatment to time of patient discharge (an average of three hours, less than one day)
Secondary	Total dose of insulin	Calculate total dosage of insulin administered to each patient	time of intervention to time of patient discharge (an average of three hours, less than one day)
Secondary	Change in glucose concentration from baseline to one, two and three hours post treatment	Change in glucose concentration from baseline (prior to insulin administration) to one hour, two hours and three hours (if patient present) after insulin administration	time of baseline BG to time of last BG measurement (prior to discharge, less than one day)
Secondary	Number of perioperative complications	Investigators will record the number of perioperative complications (cardiovascular, respiratory or other medical complications) or need for hospital admission	start of surgery to time of patient discharge (less than one day)